中文名 | S18-000003 |
英文名 | S18-000003 |
别名 | 化合物S18-000003 |
英文别名 | S18-000003 Benzeneacetamide, N-(2,4-difluorophenyl)-4-[[2-[4-(ethylsulfonyl)phenyl]acetyl]amino]-2-fluoro-α,α-dimethyl- |
CAS | 2068119-11-7 |
化学式 | C26H25F3N2O4S |
分子量 | 518.55 |
密度 | 1.358±0.06 g/cm3(Predicted) |
沸点 | 746.1±60.0 °C(Predicted) |
溶解度 | 溶于DMSO |
酸度系数 | 11.82±0.70(Predicted) |
存储条件 | -20℃ |
靶点 | RORγt,29 nM |
体外研究 | S18-000003 inhibits human and mouse RORγt-dependent transactivation, with IC 50 s of 0.029 and 0.34 μM respectively in cell-based GAL4 promoter reporter assays. S18-000003 (0.003-0.3 μM; 7 d) dose-dependently inhibits Th17 cell differentiation from human naive CD4 + T cells, with an IC 50 of 0.024 μM. S18-000003 (0.1-3 μM; 4 d) inhibits the differentiation of mouse Th17 cells from splenic naive CD4 + T cells, with an IC 50 of 0.20 μM. S18-000003 (0.03-1 μM; 3 d) reduces the IL-17 production in human PBMCs in a dose-dependent manner, and does not inhibit either the production of other cytokines (IL-2, IL-4, IL-10 and IFN-g) or cell proliferation. S18-000003 (0.1-3 μM; 3 d) reduces IL-17 and IL-22 production in PBMCs from psoriatic mice in a dose-dependent manner. |
体内研究 | S18-000003 (30-100 mg/kg; p.o.) inhibits IL-17 production in the skin of IL-23-treated mice in a dose-dependent manner. S18-000003 (0.1-8%; 100mL; topically administration once daily for 14 days) ameliorates psoriasis-like lesions in TPA-induced K14.Stat3C transgenic mice, and has little impact on the thymus. S18-000003 (0.5 mg/kg; i.v.) exhibits the half-life (3.2 h), AUC (1930 ng•h/mL), CL tot (4.33 mL/min/kg) and Vd ss in rats. S18-000003 (1 mg/kg; p.o.) exhibits the oral bioavailability (54.5%), C max (185 ng/mL), AUC (2110 ng•h/mL) and T max (4 h) in rats. |
参考资料 展开查看 | 1: Sasaki Y, Odan M, Yamamoto S, Kida S, Ueyama A, Shimizu M, Haruna T, Watanabe A, Okuno T. Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor, S18-000003. Bioorg Med Chem Lett. 2018 Dec 1;28(22):3549-3553. doi: 10.1016/j.bmcl.2018.09.032. Epub 2018 Sep 27. PubMed PMID: 30301676.[2]. Imura C, et, al. A novel RORγt inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations. J Dermatol Sci. 2019 Mar;93(3):176-185. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.928 ml | 9.642 ml | 19.285 ml |
5 mM | 0.386 ml | 1.928 ml | 3.857 ml |
10 mM | 0.193 ml | 0.964 ml | 1.928 ml |
5 mM | 0.039 ml | 0.193 ml | 0.386 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!